A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.

Cancer cells | Image credit: Sodapeaw - stock.adobe.com

In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

By Jared Kaltwasser

October 11th 2024

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

Doctor consulting with patient | Image credit: ARMMY PICCA - stock.adobe.com

JAK Inhibitors Show Promise in Concurrent Myeloid Disorders, IADs

By AJMC Contributor

October 4th 2024

In recent years, it’s been estimated that 10% to 28% of patients with myeloid disorders develop adult onset inflammatory and autoimmune disorders (IADs), complicating treatment.

Hemoglobin is responsible for transporting oxygen throughout the body, which is imperative for a multitude of functions | image credit: Justlight - stock.adobe.com

Low Hemoglobin, IDH2 Mutation Indicative of Poor Survival in MDS

By Nameera Temkar, MD

September 21st 2024

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.

Celiac disease and the body | Image Credit: reineg-stock.adobe.com

Celiac Disease Associated With Varying Risks for Cancers

By Karen Jacobson-Sive

September 13th 2024

Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin cancers, but presents a lower risk for respiratory malignancies.

<1 2 3 4 5

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions